Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 897-908

  Apte, Sachin M ^a   Fan, Dominic ^a   Killion, Jerald J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULAR TARGETING AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 1042301958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1151-3     Document Type: Article

References (71)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA - Cancer J. Clin., 53: 5-26, 2003.
2. Oriel, K. A., Hartenbach, E. M., and Remington, P. L. Trends in United States ovarian cancer mortality, 1979-1995. Obstet. Gynecol., 93: 30-33, 1999.
3. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med., 329: 1550-1559, 1993.
4. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
5. Bookman, M. A., McGuire, W. P., III, Kilpatrick, D., Keenan, E., Hogan, W. M., Johnson, S. W., O'Dwyer, P., Rowinsky, E., Gallion, H. H., and Ozols, R. F. Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the Gynecol. Oncol. Group. J. Clin. Oncol., 14: 1895-1902, 1996.
6. Gore, M. E. Treatment of relapsed epithelial ovarian cancer. In: American Society of Clinical Oncology 2001 Education Book, pp. 468-476. Alexandria, VA: ASCO, 2001.
7. Fudge, K., Bostwick, D. G., and Steams, M. E. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate, 29: 282-286, 1996.
8. Pirtskhalaishvili, G., and Nelson, J. B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate, 44: 77-87, 2000.
9. Sitaras, N. M., Sariban, E., Bravo, M., Pantazis, P., and Antoniades, H. N. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res., 48: 1930-1935, 1988.
10. Shawver, L. K., Schwartz, D. P., Mann, E., Chen, H., Tsai, J., Chu, L., Taylorson, L., Longhi, M., Meredith, S., Germain, L., Jacobs, J. S., Tang, C., Ullrich, A., Berens, M. E., Hersh, E., McMahon, G., Hirth, K. P., and Powell, T. J. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin. Cancer Res., 3: 1167-1177, 1997.
11. Uehara, H., Kim, S., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., and Fidler, I. J. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of prostate cancer bone metastasis. J. Natl. Cancer Inst. (Bethesda), 95: 558-570, 2003.
12. Antoniades, H. N., Galanopoulos, T., Neville-Golden, J., and O'Hara, C. J. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo PDGF and PDGF-receptor mRNAs and their protein products. Proc. Natl. Acad. Sci. USA, 89: 3942-3946, 1992.
13. Lindmark, G., Sundberg, C., Glimelius, B., Pahlman, L., Rubin, K., and Gerdin, B. Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab. Investig., 69: 682-689, 1993.
14. Seymour, L., Dajee, D., and Bezwoda, W. R. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res. Treat., 26: 247-252, 1993.
15. Yi, B., Williams, P. J., Niewolna, M., Wang, Y., and Yoneda, T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res., 62: 917-923, 2002.
16. George, D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol., 28: 27-33, 2001.
17. Fleming, T. P., Saxena, A., Clark, W. C., Robertson, J. T., Oldfield, E. H., Aaronson, S. A., and Ali, I. U. Amplification and/or overexpression of platelet-derived growth, factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res., 52: 4550-4553, 1992.
18. Guha, A., Dashner, K., Black, P. M., Wagner, J. A., and Stiles, C. D. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer, 60: 168-173, 1995.
19. Ostman, A., and Heldin, C. H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res., 80: 1-38, 2001.
20. Dabrow, M. B., Francesco, M. R., McBrearty, F. X., and Caradonna, S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol. Oncol., 71: 29-37, 1998.
21. Henriksen, R., Funa, K., Wilander, E., Backstrom, T., Ridderheim, M., and Oberg, K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res., 53: 4550-4554, 1993.
22. Versnel, M. A., Haarbrink, M., Langerak, A. W., de Laat, P. A., Hagemeijer, A., van der Kwast, T. H., van den Berg-Bakker, L. A., and Schrier, P. I. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet. Cytogenet., 73: 60-64, 1994.
23. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
24. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295: 139-145, 2000.
25. Ebert, M., Yokoyama, M., Friess, H., Kobrin, M. S., Buchler, M. W., and Korc, M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer, 62: 529-535, 1995.
26. Druker, B. J., and Lydon, N. B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia (Perspective). J. Clin. Investig., 105: 3-7, 2000.
27. Druker, B. J., Talpaz, M., Resta, D., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
28. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B. J., and Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med., 344: 1052-1056, 2001.
29. Sjoblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Dal Cin, P., Buchdunger, E., Dumanski, J. P., Ostman, A., and Heldin, C-H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res., 61: 5778-5783, 2001.
30. Ahluwalia, A., Hurteau, J. A., Bigsby, R. M., and Nephew, K. P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol. Oncol., 82: 299-304, 2001.
31. Buick, R. N., Pullano, R., and Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res., 45: 3668-3676, 1985.
32. Xu, L., and Fidler, I. J. Acidic pH-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res., 60: 4610-4616, 2000.
33. Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., and Hung, M. C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res., 53: 891-898, 1993.
34. Fogh, J., and Trempe, G. (eds.). Human Tumor Cells in Vitro. New York: Plenum Press, 1975.
35. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. (Bethesda), 90: 447-454, 1998.
36. Fan, D., Poste, G., Seid, C., Earnest, L. E., Bull, T., Clyne, R. K., and Fidler, I. J. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Investig. New Drugs, 12: 185-195, 1994.
37. Baker, C. H., Kedar, D., McCarty, M. F., Tsan, R., Weber, K. L., Bucana, C. D., and Fidler, I. J. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am. J. Pathol., 161: 929-938, 2002.
38. Kim, S. J., Uehara, H., Karashima, T., Shepherd, D. L., Killion, J. J., and Fidler, I. J. Blockade of epidermal growth factor-receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res., 9: 1200-1210, 2003.
39. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-31, 1995.
40. Ellis, L. M., and Fidler, I. J. Tumor angiogenesis. In: J. Mendelsohn, P. M. Howley, M. A. Israel, and L. A. Liotta, (eds.), The Molecular Basis of Cancer, Ed. 2, pp. 173-185. Philadelphia: W. B. Saunders, 2001.
41. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
42. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB. Nature (Lond.), 385: 544-548, 1997.
43. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev., 11: 701-713, 1997.
44. Pietras, K., Sjöblom, T., Rubin, K., Heldin, C-H., and Östman, A. PDGF receptors as cancer drug targets. Cancer Cell, 3: 439-443, 2003.
45. Fidler, I. J. The organ microenvironment and cancer metastasis (Review). Differentiation, 70: 498-505, 2002.
46. Hobson, B., and Denekamp, J. Endothelial proliferation in tumours and normal tissues: continuous labeling studies. Br. J. Cancer, 49: 405-413, 1984.
47. Bocci, G., Nicolson, K. C., and Kerbel, R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res., 62: 6938-6943, 2002.
48. Bar, R. S., Boes, M., Booth, B. A., Dake, B. L., Henley, S., and Hart, M. N. The effects of platelet-derived growth factor in cultured microvessel endothelial cells. Endocrinology, 124: 1841-1848, 1989.
49. Beitz, J. G., Kim, I. S., Calabresi, P., and Frackelton, A. R., Jr. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc. Natl. Acad. Sci. USA, 88: 2021-2025, 1991.
50. Marx, M., Perlmutter, R. A., and Madri, J. A. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J. Clin. Investig., 93: 131-139, 1994.
51. Holmgren, L., Glaser, A., Pfeifer-Ohlsson, S., and Ohlsson, R. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development (Camb.), 113: 749-754, 1991.
52. Plate, K. H., Breier, G., Farrell, C. L., and Risau, W. Platelet-derived growth factor receptor β is induced during tumor development and up-regulated during tumor progression in endothelial cells in human gliomas. Lab. Investig., 67: 529-534, 1992.
53. Risau, W., Drexler, H., Mironov, V., Smits, A., Siegbahn, A., Funa, K., and Heldin, C. H. Platelet-derived growth factor is angiogenic in vivo. Growth Factors, 7: 261-266, 1992.
54. Oikawa, T., Onozawa, C., Sakaguchi, M., Morita, I., and Murota, S. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol. Pharm. Bull., 17: 1686-1688, 1994.
55. Nicosia, R. F., Nicosia, S. V., and Smith, M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am. J. Pathol., 145: 1023-1029, 1994.
56. Reuterdahl, C., Sundberg, C., Rubin, K., Funa, K., and Gerdin, B. Tissue localization of β receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans. J. Clin. Investig., 91: 2065-2075, 1993.
57. Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H., and Pech, M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β receptors. J. Cell Biol., 125: 917-928, 1994.
58. Westermark, B., Siegbahn, A., Heldin, C. H., and Claesson-Welsh, L. B-Type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. Proc. Natl. Acad. Sci. USA, 87: 128-132, 1990.
59. Koyama, N., Watanabe, S., Tezuka, M., Morisaki, N., Saito, Y., and Yoshida, S. Migratory and proliferative effect of platelet-derived growth factor in rabbit retinal endothelial cells: evidence of an autocrine pathway of platelet-derived growth factor. J. Cell. Physiol., 158: 1-6, 1994.
60. Iguchi, I., Kamiyama, K., Wang, X., Kita, M., Imanishi, J., Yamaguchi, N., Sotozono, C., and Kinoshita, S. Enhancing effect of platelet-derived growth factors on migration of corneal endothelial cells. Cornea, 14: 365-371, 1995.
61. Sano, H., Ueda, Y., Takakura, N., Takemura, G., Doi, T., Kataoka, H., Murayama, T., Xu, Y., Sudo, T., Nishikawa, S., Fujiwara, H., Kita, T., and Yokode, M. Blockade of platelet-derived growth factor receptor β pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am. J. Pathol., 161: 135-143, 2002.
62. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Wash. DC), 277: 242-245, 1997.
63. Sundberg, C., Ljungstrom, M., Lindmark, G., Gerdin, B., and Rubin, K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol., 143: 1377-1388, 1993.
64. Crosby, J. R., Seifert, R. A., Soriano, P., and Bowen-Pope, D. F. Chimaeric analysis reveals role of PDGF receptors in all muscle lineages. Nat. Genet., 18: 385-388, 1998.
65. Chaudhary, L. R., and Hruska, K. A. The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells. J. Cell. Biochem., 81: 304-311, 2001.
66. Romashkova, J. A., and Makarov, S. S. NF-κB is a target of AKT in anti-apoptotic PDGF signaling. Nature (Lond.), 401: 86-90, 1999.
67. Pietras, K., Rubin, K., Sjoblom, T., Buchdunger, E., Sjoquist, M., Heldin, C. H., and Ostman, A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res., 62: 5476-5484, 2002.
68. Yoon, S. Y., Tefferi, A., and Li, C. Y. Cellular distribution of platelet-derived growth factor, transforming growth factor β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol., 104: 151-157, 2000.
69. Thyberg, J. The microtubular cytoskeleton and the initiation of DNA synthesis. Exp. Cell Res., 155: 1-8, 1984.
70. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
71. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited (Timeline). Nat. Rev. Cancer, 9: 453-458, 2003.